Boehringer Ingelheim enters collaboration on hearing loss treatment for up to USD 100m

Biotech firm Autigen has inked a research collaboration and license agreement with Boehringer Ingelheim to discover and develop treatments for hearing loss.

Photo: Joachim Adrian/Politiken/Ritzau Scanpix

German Boehringer Ingelheim and US-based biotech firm Autigen are partnering up to discover and develop potential hearing loss treatments, the company has announced in a press release on Wednesday, as reported by industry media Fierce Biotech.

Under the terms, Boehringer makes an undisclosed upfront payment to Autigen, funding the firm’s research into a drug that will restore sensory hair cells. When these are damaged, it can lead to the inner-ear condition known as sensorineural hearing loss (SNHL).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs